Biomarkers of immunotherapy in non‑small cell lung cancer (Review)

Abstract

Immunotherapy has markedly improved the survival rate of patients with non‑small cell lung cancer (NSCLC) and has introduced a new era in lung cancer treatment. However, not all patients with lung cancer benefit from checkpoint blockade, and some suffer from notable immunotoxicities. Thus, it is crucial to identify potential biomarkers suitable for screening the population that may benefit from immunotherapy. Based on the current clinical trials, the aim of the present study was to review the biomarkers for immune checkpoint inhibition, as well as other effective, invalid and hyperprogression markers that may have the potential to better predict responders to immunotherapy among patients with NSCLC. All these biomarkers may be incorporated into the predictive utility of bio‑score systems and decision‑making algorithms, to better guide the application of immunotherapy in the clinical setting.